Bob Press

Radiation Oncologist, Clinical Director of Proton Therapy, Lynn Cancer Institute, Baptist Health South Florida

[Bob Press @DrBPress]

@WaltEcton Congrats Walt!

[Bob Press @DrBPress]

@ParikhSimul @itscharliework Aviva by Kameel
Lottafrutta
The Albert
The Porter
Storico Fresco

[Bob Press @DrBPress]

@LiorBraunstein @CChinMD

[Bob Press @DrBPress]

Looking forward to these exciting #radonc presentations at the @NYRS_RFS Annual Meeting this afternoon! @MikeChuongMD @DHorowitzMD @RadOnc_MD @SJFrankMD

Talks are virtual and open to all. To register: https://t.co/AirM6YzRIq

[Bob Press @DrBPress]

@MohammadKhanMD @EmoryUniversity @WinshipAtEmory @ASTRO_org @ASCO Congrats!

[Stuart Burri, M.D. @stuxrt]

After a decade plus of hard work delighted to say that @NRGonc BN-012 randomized phase III trial of pre-op vs post-op SRS for resected brain metastases is slated to open this week! #radonc and #Neurosurgery let’s enroll and answer this important #timing question.

[Bob Press @DrBPress]

@DrWuRadOnc Would love to Fred! Just know that at NYPC we can only hit drop shots 😉🎾 @ShaakirHasan

[Bob Press @DrBPress]

@ParikhSimul Condolences Simul. Lovely tribute and photos. Very sorry for your loss.

[Hyun Kim @adapthyun]

Excited to share the first prospective study of MR guided RT in #PancreaticCancer @IJROBP. Ablative RT with concurrent full dose chemo. All tumors abutted at least 1 OAR. 2-yr LC 85%. Median OS for ECOG 0 and CA 19-9<90 pts were 34 and 43 mos.

https://t.co/AwJp296FMP

[University of Michigan @UMich]

Join us in offering a very warm #Wolverine welcome to Dr. Santa J. Ono, named today by the Board of Regents as 15th President-Elect of the University of Michigan. We look forward to having Dr. @SantaJOno on campus this fall. https://t.co/6JNzstRgqL #GoBlue #UMichPres15

[Bob Press @DrBPress]

Congrats Santa! @ubcprez Everywhere you go, you make a huge impact @EmoryUniversity @uofcincy @UBC @UMich is lucky to have you lead them next!

[Benoit-Antoine Bacon @ubcprez]

It has been an honour and privilege to serve the University of British Columbia. I shall forever be proud of what we have accomplished together. UBC and the many friends we have made in the UBC family will always be close to our hearts.

https://t.co/vg05wAYQXe

[NASA Webb Telescope @NASAWebb]

👀 Sneak a peek at the deepest & sharpest infrared image of the early universe ever taken — all in a day’s work for the Webb telescope. (Literally, capturing it took less than a day!) This is Webb’s first image released as we begin to #UnfoldTheUniverse: https://t.co/tlougFWg8B

[Bob Press @DrBPress]

@wallyjc @WinshipAtEmory @ASTRO_org @NRGonc @EmoryRadOncRes @EmoryMedicine Congrats @PeteRossiMD! Phenomenal physician and mentor. I’m grateful to have trained with you.

[Bob Press @DrBPress]

@MarkMishraMD @RTOGFoundation @NRGonc Congrats Mark!

[Bob Press @DrBPress]

@TNradonc Awful news, so sorry Casey.

[Bob Press @DrBPress]

Excited to have THE Dr. Beriwal present on the management of cervical cancer at the next NYRS meeting⚡️All are welcome. Meeting details in the link below.

[Stanislav (Stas) Lazarev, MD @StasLazarev]

@ParikhSimul @blally_md @SprakerMDPhD It actually has to do with the field of RT, not technique. With pCSI, we are able to utilize marrow-sparing technique (essentially treating just the thecal sac) hence, pts tolerate pCSI without any meaningful GI/heme toxicity and can continue systemic tx for extraCND disease

[Bob Press @DrBPress]

@blally_md @rlevitinMD @JYangMDPhD @SprakerMDPhD @ParikhSimul Improves CNS PFS with some achieving durable control. This as a win for patients.

Important caveat: Patient selection is critical. Not for all comers.

[Bob Press @DrBPress]

@blally_md @rlevitinMD @JYangMDPhD @SprakerMDPhD @ParikhSimul These results don’t need to be controversial. The technology enables you to deliver a “better” treatment (sterilize the entire CSF which has disseminated disease) with the equivalent toxicity of IFRT (avoiding bone marrow, N/V, esophagitis, etc).

[Bob Press @DrBPress]

Congrats @JYangMDPhD et al. on this important study. This marks the 5th completed randomized proton/photon trial and the first to demonstrate an OS benefit. Grateful we are moving the needle for our patients with devastating leptomeningeal disease.

[Matt Spraker @SprakerMDPhD]

Phase II trial of Proton CSI versus photon IFRT for breast or NSCLC leptomeningeal disease shows a survival benefit for protons at #ASCO22 #radonc

Nice study!

https://t.co/qYdeo2MZCa